Compare Emerson Electric Co. (EMR) vs Cassava Sciences Inc (FLNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Emerson Electric Co. vs Cassava Sciences Inc — how do they compare? Emerson Electric Co. trades at $137.76 (market cap $76.31B), while Cassava Sciences Inc trades at $1.08 (market cap $53.14M). The key difference: Emerson Electric Co. is far larger — about 1436× Cassava Sciences Inc's market cap, and Emerson Electric Co. pays a 1.63% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.
| EMR | FLNA | |
|---|---|---|
Market Cap | $76.31B | $53.14M |
Sector | Industrials | Health |
52-Week High | $161.69 | $4.64 |
52-Week Low | $123.30 | $1.09 |
Enterprise Value | $88.58B | -$33.43M |
Dividend Yield | 1.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Emerson Electric (EMR) trades at $136.11, showing modest daily gains amid a bearish technical signal. The company maintains solid fundamentals with a 13.35% net income margin and recent earnings beats, though valuation multiples like a P/E of 31.54 appear elevated. Analyst consensus is bullish with a $157.60 price target, but cash flow volatility and a high debt-to-asset ratio of 31.26% in 2025 pose concerns. Recent news highlights upcoming Q3 2026 earnings and growth in the Intelligent Devices segment.
EMR offers a balanced risk-reward profile; strong profitability and analyst support suggest upside, but technical weakness and financial leverage require caution. The stock's trajectory hinges on sustaining earnings momentum and managing debt, with key resistance near $137.
Filana Therapeutics (FLNA) trades at $1.09, down 5.22% on the day, reflecting persistent operational losses despite recent earnings beats. The stock exhibits a strong bearish technical signal, with moving averages and oscillators aligned negatively. Fundamentally, the company is in a pre-revenue biotech development phase, evidenced by significant negative cash flow from operations (-$32.25M in 2025) and deeply negative profitability metrics (ROE: -79.59%). Recent news highlights continued focus on its Tuberous Sclerosis Complex (TSC)-related epilepsy program.
The outlook is bifurcated: a bullish analyst consensus (8 Buy, 4 Hold, 0 Sell) suggests optimism for the clinical pipeline, while severe financial burn and bearish technicals present substantial near-term risk. Investment opportunity hinges entirely on successful drug development, with significant dilution or financing risk as the company funds operations. The stock is suitable only for high-risk investors comfortable with binary clinical outcomes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Emerson Electric Co.
Emerson Electric is a multi-industrial conglomerate that operates under two business platforms: automation solutions and commercial and residential solutions. The latter is further subdivided into two operating segments: climate technologies, which sells HVAC and refrigeration products and services as well as tools and home products, which sells tools and compressors, among other products and services. Commercial and residential solutions boasts several household brands, including Copeland and RIDGID. Automation solutions is most known for its process manufacturing solutions, which consists of measurement instrumentation, as well as valves and actuators, among other products and services. Roughly half of the firm's geographic sales take place in the United States.
Read more on EMR →About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →
